Humacyte (HUMA) Q4 2025 earnings summary

Executive summary

• Achieved continued execution of the U.S. commercial launch of Symvess and expanded efforts into international markets, including a $1.475 million purchase commitment in Saudi Arabia and a marketing application in Israel.

• Secured 27 VAC approvals in the U.S. with a 70% success rate and 27 hospitals ordering Symvess, most with repeat orders.

• U.S. Department of Defense allocated funding for evaluation and procurement of biologic vascular repair technologies.

• Published long-term safety and efficacy data for Symvess in trauma and dialysis access, supporting adoption.

• Advanced pipeline with positive preclinical results for coronary tissue engineered vessel (CTEV) and plans for first-in-human studies in 2026.

Financial highlights

• Q4 2025 revenue was $0.5 million, with $0.4 million from U.S. Symvess sales; full-year 2025 revenue was $2.0 million, with $1.4 million from Symvess and $0.6 million from research collaborations.

• Cost of goods sold for 2025 was $9.7 million, including an $8.9 million inventory reserve due to limited sales history.

• R&D expenses decreased to $69.3 million for 2025 from $88.6 million in 2024, reflecting transition to commercial operations.

• SG&A expenses rose to $31.2 million in 2025 from $25.8 million in 2024, driven by commercial launch activities.

• Net loss for 2025 was $40.8 million, a significant improvement from $148.7 million in 2024, aided by reduced R&D expenses and new financing.

Outlook and guidance

• Interim results from the V012 phase III trial in women for dialysis access expected by early June 2026.

• Plan to submit a supplemental BLA for dialysis access in the second half of 2026, pending positive interim results.

• First-in-human phase I/II study for CTEV in coronary artery bypass planned for the second half of 2026, pending FDA clearance.

• No formal revenue or cash burn guidance provided for 2026; growth expected to be gradual.